Xenetic Biosciences is trading at $1.68, down 9.68%, with the November 6 after-hours decline’s catalyst unclear.
- No clear company-specific news or announcement explaining the decline was identified.
- The latest company release found was November 4, announcing an oral presentation at the December ASH meeting—a prior scientific update, not a new November 6 event.
- The Nasdaq rose 1.75% and the S&P 500 gained 0.45% while Xenetic Biosciences moved lower.